Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Introduction: Ketamine has emerged as a rapid-acting antidepressant. While ongoing treatment can prevent relapse, concerns exist regarding long-term exposure. Objective: We conducted a randomized trial to examine the feasibility and efficacy of cognitive behavioral therapy (CBT) following intravenous ketamine in treatment-resistant depression (TRD). Methods: Subjects with TRD were recruited and treated with 6 intravenous infusions of ketamine over 3 weeks. Subjects who experienced a clinical response (≥50% improvement in depression severity) were then randomized to receiving CBT or treatment as usual (TAU) for an additional 14 weeks, using a sequential treatment model. Results: Of the 42 patients who signed consent, 28 patients achieved a response and were randomized to CBT or TAU. When measured using the Montgomery-Asberg Depression Rating Scale (primary outcome measure), the effect size at the end of the study was moderate (Cohen d = 0.65; 95% CI –0.55 to 1.82), though the group-by-time interaction effect was not significant. There was a significant group-by-time interaction as measured by the Quick Inventory of Depressive Symptomatology (F = 4.58; p = 0.033), favoring a greater sustained improvement in the CBT group. This corresponded to a moderate-to-large effect size of the Cohen d = 0.71 (95% CI –0.30 to 1.70) at the end of the study (14 weeks following the last ketamine infusion). In a subset of patients (N = 20) who underwent cognitive testing using the emotional N-back assessments before and after ketamine, ketamine responders showed improvement in the accuracy of emotional N-back (t[8] = 2.33; p < 0.05) whereas nonresponders did not (t[10] <1; p ns). Conclusions: This proof-of-concept study provides preliminary data indicating that CBT may sustain the antidepressant effects of ketamine in TRD. Further study and optimization of this treatment approach in well-powered clinical trials is recommended.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another randomized trial (n = 28) found that cognitive behavioral therapy in addition to repeated ketamine infusions (six infusions over three weeks) generated greater sustained improvement than ketamine alone [57].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [57]
In the citing paper
“Moreover, the concomitant administration of ketamine and psychological interventions ('ketamine- as sisted' therapy) is insufficiently character ized and as such cannot be recommended for TRD 202 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [202]
In the citing paper
“Preliminary evidence suggests that CBT may be capable of prolonging the effect observed in adults with TRD who acutely benefited from ketamine treatment 202 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [202]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Self-citationNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Individual differences in executive functions are almost entirely genetic in origin.
Friedman, N. P., Miyake, A., Young, S. E., DeFries, J. C., Corley, R. P., & Hewitt, J. K. (2008) · Journal of Experimental Psychology: General · doi:10.1037/0096-3445.137.2.201 · Cited by 1,547
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
TRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
Research works printed but not linked: 1
- 10.1037/0022-006x.69.6.914 · doi:10.1037/0022-006x.69.6.914 · Paper page
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationKetamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“Pilot studies have described bene fi cial effects where ketamine has been combined with CBT [61] and a digital intervention.”
BackgroundGrabski, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., Hardy, L., Warren, F., Bloomfield, M., Borissova, A., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21030277 · Cited by 175
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
“A recent follow-up study randomized 28 patients who had achieved response after six ketamine infusions to receive either CBT or treatment as usual [67].”
BackgroundInfluentialKetamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J. D., Ritvo, P., Mattina, G. F., Bhat, V., Diep, C., & Ladha, K. S. (2022) · Journal of Pain Research · doi:10.2147/jpr.s360733 · Cited by 151
Long-term safety of ketamine and esketamine in treatment of depression
Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066651 · Cited by 120
Self-citationJha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 114
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Gkintoni, E., Vassilopoulos, S. P., & Νικολάου, Γ. (2025) · Medicina · doi:10.3390/medicina61030431 · Cited by 94
Krystal, J. H., Kaye, A. P., Jefferson, S., Girgenti, M. J., Wilkinson, S. T., Sanacora, G., & Esterlis, I. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305772120 · Cited by 91
Self-citationPrice, R. B., Spotts, C., Panny, B., Griffo, A., Degutis, M., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., Mathew, S. J., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220216 · Cited by 85
“Consistent with rising momentum in the creation of synergistic biobehavioral approaches to psychiatric management (including both ketamine [28 – 30] and other “ psychoplastogenic ” drugs [31]), the present study was designed to push the boundaries of how rapid-acting anti-depressant drug agents…”
A unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 78
Toward Synergies of Ketamine and Psychotherapy
Mathai, D. S., Mora, V., & Garcia‐Romeu, A. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.868103 · Cited by 74
Ketamine and psychotherapy for the treatment of psychiatric disorders: Systematic review
Kew, B. M., Porter, R. J., Douglas, K. M., Glue, P., Mentzel, C. L., & Beaglehole, B. (2023) · BJPsych Open · doi:10.1192/bjo.2023.53 · Cited by 69
Active mechanisms of ketamine-assisted psychotherapy: A systematic review
Joneborg, I., Lee, Y. L., Vincenzo, J. D. D., Ceban, F., Meshkat, S., Lui, L. M. W., Fancy, F., Rosenblat, J. D., & McIntyre, R. S. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.030 · Cited by 61
New and emerging treatments for major depressive disorder
Njenga, C., Ramanuj, P., de Magalhães, F. J. C., & Pincus, H. A. (2024) · BMJ · doi:10.1136/bmj-2022-073823 · Cited by 59
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
The need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 43
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 40
Rothärmel, M., Benosman, C., El‐Hage, W., Berjamin, C., Ribayrol, D., Guillin, O., Gaillard, R., Berkovitch, L., & Moulier, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.865466 · Cited by 40
Havlik, J. L., Wahid, S., Teopiz, K. M., McIntyre, R. S., Krystal, J. H., & Rhee, T. G. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01494-4 · Cited by 36
Self-citationStaging of unipolar depression: systematic review and discussion of clinical implications
Cosci, F., & Fava, G. A. (2022) · Psychological Medicine · doi:10.1017/s0033291722001507 · Cited by 28
Breeksema, J. J., Niemeijer, A. R., Kuin, B., Veraart, J. K. E., Vermetten, E. H. G. J. M., Kamphuis, J., van den Brink, W., & Schoevers, R. A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06388-6 · Cited by 34
Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression
Zavaliangos‐Petropulu, A., McClintock, S. M., Khalil, J., Joshi, S. H., Taraku, B., Al‐Sharif, N., Espinoza, R. T., & Narr, K. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.015 · Cited by 27
Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression
Gałuszko‐Węgielnik, M., Chmielewska, Z., Jakuszkowiak‐Wojten, K., Wiglusz, M. S., & Cubała, W. J. (2023) · Brain Sciences · doi:10.3390/brainsci13010142 · Cited by 23
Walther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 22
Ketamine and Esketamine for Depression in Daily Practice: Opportunities and Challenges
Singh, B. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001898 · Cited by 20
Psychedelics and Evidence-based Psychotherapy
Leone, L., McSpadden, B., DeMarco, A., Enten, L., Kline, R., & Fonzo, G. A. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.02.006 · Cited by 19
Martiadis, V., Raffone, F., Testa, S., Iaccarino, C., Giunnelli, P., Orrico, A., Carbone, E., Clemente, S., Simone, C. D., Massa, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041629 · Cited by 19
Aepfelbacher, J., Panny, B., & Price, R. B. (2024) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2024.100316 · Cited by 18
Tsang, V. W. L., Ragazan, D. C., Kryskow, P., Walsh, Z., & Dames, S. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2253798 · Cited by 17
Rhee, T. G., Bommersbach, T. J., Rosenheck, R. A., Nierenberg, A. A., & McIntyre, R. S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.044 · Cited by 17
Self-citationMoore, T. M., Walker, K. C., Tung, E., Teed, A. R., Hell, F., Kinreich, S., Jung, R., Abdel, F., Hanson, R. W., & Ahmed, S. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.041 · Cited by 15
The Role of Psychotherapy in the Management of Treatment-Resistant Depression
Rogan, T., & Wilkinson, S. T. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.006 · Cited by 15
Self-citationBranchi, I. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16331 · Cited by 14
Sajid, S., Galfalvy, H., Keilp, J. G., Burke, A. K., Mann, J. J., & Grunebaum, M. F. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae017 · Cited by 15
Synaptic priming: A framework for pharmacotherapy in depression
Brown, K. A., Ajibola, M. I., Medeiros, G. C., & Gould, T. D. (2025) · Neuron · doi:10.1016/j.neuron.2025.09.010 · Cited by 13
Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review
FREIND, J. M. K., Beserra, F. R., Menezes, B. S., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2248989 · Cited by 13
Kitay, B. M., Murphy, E., Macaluso, M., Corlett, P. R., Hershenberg, R., Joormann, J., Martinez‐Kaigi, V., Nikayin, S., Rhee, T. G., Sanacora, G., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115585 · Cited by 13
Self-citationA novel framework for ketamine-assisted couple therapy
Khalifian, C. E., Rashkovsky, K. T., Mitchell, E., Bismark, A. W., Wagner, A. C., & Knopp, K. C. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1376646 · Cited by 12
Kaltenboeck, A., Foerster, E., Strafner, S., Demal, U., Mossaheb, N., & Friedrich, F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1291077 · Cited by 11
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Więdłocha, M., Marcinowicz, P., Komarnicki, J., Tobiaszewska, M., Dębowska, W., Dębowska, M. D., & Szulc, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1398859 · Cited by 11
Hussain, S., Gale, C. K., Sarma, S., Smith, J. P., Bayes, A. J., & Loo, C. K. A. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251333577 · Cited by 11
The why, when, where, how, and so what of so-called rapidly acting antidepressants
Schatzberg, A. F., & Mathew, S. J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01647-8 · Cited by 11
Kim, S., Yang, S., Jung, J., Choi, J., Kang, M., & Joo, J. (2025) · Advanced Science · doi:10.1002/advs.202413786 · Cited by 10
Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review
Veraart, J. K. E., Schimmers, N., Breeksema, J. J., Seybert, C., Kamphuis, J., Huber, L. F. T., Rota, A., Coerts, D. T., Oliveira-Maia, A. J., & Schoevers, R. A. (2026) · Clinical Psychology Review · doi:10.1016/j.cpr.2026.102706 · Cited by 9
Beaglehole, B., Porter, R., Douglas, K. M., Lacey, C. J., de Bie, A., Jordan, J., Mentzel, C., Thwaites, B., Manuel, J., Murray, G., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084844 · Cited by 9
Psychedelics and psychoanalysis: The journey from talking cure to transformation
Lichtenstein, J., & Hoeh, N. R. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00373 · Cited by 9
Singanwad, P., Tatode, A., Qutub, M., Taksande, B. G., Umekar, M. J., Trivedi, R., & Premchandani, T. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102538 · Cited by 9
Morales, C., Luks, K. L., & Sibrava, N. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91497-0.00206-x · Cited by 9
Ketamine-Assisted Psychotherapy for Antisocial Personality Disorder: A Case Report
Hicks, M., Zwickey, H. L., & Bradley, R. D. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2449911 · Cited by 8
Suicide prevention and ketamine: insights from computational modeling
Charlton, C. E., Karvelis, P., McIntyre, R. S., & Diaconescu, A. O. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1214018 · Cited by 7
Weintraub, M. J., Jeffrey, J. K., Grob, C. S., Ichinose, M. C., Bergman, R. L., Cooper, Z. D., & Miklowitz, D. J. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0018 · Cited by 7
Phillips, J. L., Blier, P., & Talbot, J. D. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100613 · Cited by 6
Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment
Silczuk, A., Madejek, R., Koweszko, T., Mularczyk-Tomczewska, P., Adamska, E., Gujski, M., & Szulc, A. (2025) · Medical Science Monitor · doi:10.12659/msm.948302 · Cited by 6
RETRACTED–Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study
Mills, N. T., Nikolin, S., Glozier, N., Barton, D., Baune, B. T., Fitzgerald, P. B., Glue, P., Sarma, S., Rodgers, A., Hadzi-Pavlovic, D., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.250 · Cited by 5
RetractedGiguère, S., Fortier, A., Azrak, J., Giguère, C., Potvin, S., & Dumais, A. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080338 · Cited by 5
Simpson, R. J., & Juruena, M. F. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07003-0 · Cited by 5
Lin, W., Su, T., Li, C., Wu, H.-J., Tsai, S., Bai, Y., Tu, P., & Chen, M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231182107 · Cited by 5
Giguère, S., Potvin, S., Fortier, A., Phraxayavong, K., Lespérance, F., Do, A., Bahremand, A., & Dumais, A. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117080 · Cited by 4
Dölen, G., & Wilkinson, M. L. (2026) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-112723-045129 · Cited by 4
Earleywine, M., Falabella, G. S., Oliva, A. B., & Low, F. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2421892 · Cited by 4
Fava, G. A. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001468 · Cited by 4
Weintraub, M. J., Miklowitz, D. J., & Jeffrey, J. K. (2025) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000853 · Cited by 3
Ketamine Integration Chaplaincy: A Novel Spiritual Care Approach to Psychedelic Integration
Breau, J. A., Gillis‐Smith, P., & Deonauth, T. (2025) · Anthropology of Consciousness · doi:10.1111/anoc.70012 · Cited by 3
Cohen, R., Bastos, J., Cunha, C., Marguilho, M., Sancho, A. V., Silva, M. J. M., King, F., & Castro-Rodrigues, P. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.02.001 · Cited by 3
Ketamine pharmacotherapy for major depressive disorder: A narrative review
Miller, C. H., Hickman, A., Baten, C., Ali, Z., Kahlon, S. K., Klassen, A. M., Zamora, G., Shepherd, J. H., Venegas, G., Miller, J. A., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111651 · Cited by 3
Schüle, C., Sobieraj, A., & Rogg, H. V. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2742-4611 · Cited by 3
Swainson, J., Grewal, P., Polard, S., Borle, C., Gutierrez, G., Zhang, Y., Winkler, O., Burback, L., Khullar, A., McIntyre, R. S., et al. (2026) · npj Mental Health Research · doi:10.1038/s44184-026-00226-1 · Cited by 3
Fletcher, K., Ezard, N., Siefried, K. J., Macdonald, H., Acheson, L. S., Bedi, G., Guerin, A. A., Knock, E., Millard, M., May, R., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-092504 · Cited by 3
Understanding the variability in ketamine’s efficacy in managing treatment-resistant depression
Bryan, J. (2024) · Discover Psychology · doi:10.1007/s44202-024-00277-5 · Cited by 3
Zambrano, J., & Forcén, F. E. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001726 · Cited by 2
Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians
Elliott, S. I., Katz, R. B., Ostroff, R. B., Ansari, M., Holmes, S. E., & Sanacora, G. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20240040 · Cited by 2
Self-citationBranchi, I. (2025) · Biological Theory · doi:10.1007/s13752-025-00505-8 · Cited by 2
Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial
Weintraub, M. J., Jeffrey, J. K., Ichinose, M. C., Bergman, R. L., Shapiro, B., Barnett, G., Artin, H., Lynn, M., Salimian, A., Grody, S., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121423 · Cited by 2
Progress, potential and pitfalls of ketamine as a treatment for depression
Orsini, D. K., Luch, S. D. D., Lovell, G. F. M., & Rosenblat, J. D. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2637587 · Cited by 2
Trajectories of late-life depression: insights from molecular imaging
Holmes, S. E., & Smith, G. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02340-2 · Cited by 2
Utilization of Ketamine for Major Depression
Dao, R., & Aggarwal, A. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00027 · Cited by 2
Morland, L. A., Knopp, K. C., Khalifian, C. E., & Stauffer, C. S. (2025) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2025.04.001 · Cited by 2
Grabski, M., & Morgan, C. J. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91497-0.00236-8 · Cited by 2
Mehtani, N. J., Anderson, B. T., Alexander, I., Hendricks, P. S., Mitchell, J., Coffin, P. O., & Johnson, M. O. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-100775 · Cited by 1
Kosted, R., Waddell, A., Adolph, K., & Fonzo, G. A. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121350 · Cited by 1
Ketamine as a Mental Health Treatment
Braun, L., & Colbert, A. M. (2026) · AJN American Journal of Nursing · doi:10.1097/ajn.0000000000000250 · Cited by 1
Varela, Y. M., Tavares, V. D. D. O., Delgado, L. M., de Faria, H. A. T., Menezes, L. Q., Almeida, R. M., Agrícola, P. M. D., de Carvalho, B. S., Bienemann, B., Falchi-Carvalho, M., et al. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02188-5 · Cited by 1
Varela, Y. M., Cavalcanti-Ribeiro, P., de Sousa, G. M., Falchi-Carvalho, M., Barbalho, J. D. S. F., Gomes, R. B. D. O., Gurgel, M. M. M., Pereira, B. C., Souza, P. M. D. L., Gonçalves, K. T. D. C., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122369 · Cited by 1
Biologisch unterstützte psychotherapeutische Interventionen bei therapieresistenten Depressionen
Richter, J., & Nazarenus, E. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_26 · Cited by 1
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Ju, W., Li, J., Qiu, L., & Wu, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2217567/v1
Therapeutic Use of Ketamine in Psychiatric Disorders
Jones, J., Morgan, C. J. A., & Malcolm, R. J. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-1050-6
Effects of Ketamine and Esketamine on Cognitive Functions in Treatment-Resistant Depression
Mutlu, M., Öven, Ç., Kurt, B. S., & SUNAY, E. (2025) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1524106
Ketamine and Esketamine in Treatment of Resistant Depression
Prosowski, J., Pośpiech, S., Piotrowski, M., Serwicki, P., & Początek, J. (2024) · Archiv Euromedica · doi:10.35630/2024/14/6.611
Priya, S., Rajini, G., & Karthikeyan, V. S. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-4014-1.ch006
Bias and balance in psychedelic academia: a tricky business
Bawks, J., & Gomes, F. A. (2025) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2024-0990
Challenges in management of treatment-resistant depression
Piech, G. M., & Lis, I. (2024) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2024-0032
Himmelseher, S., & Maani, C. V. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_25
The Global Importance of Ketamine for Medical Care
Himmelseher, S., & Pfenninger, E. G. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_1
Li, M., Şen, Z. D., Danyeli, L. V., Javaheripour, N., & Walter, M. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_14
Cetamina: um psicadélico em ascensão na depressão resistente ao tratamento
Santos, P. E. D. S. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/4crx-c978
Metadata
- Authors
- Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G.
- Affiliations
- Yale University (US)
- University of Minnesota (US)
- Emory University (US)
- ORCID
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 90
- Issue
- 5
- Pages
- 318-327
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3176790550
- Cited by
- 108
- References
- 51
- Citations by year
- 2026: 27 · 2025: 20 · 2024: 21 · 2023: 24 · 2022: 15 · 2021: 1
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R01MH125205)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- treatment-resistant depression, ketamine, cognitive behavioral therapy, rapid-acting antidepressants, cognitive flexibility, depression relapse prevention
- MeSH terms
- Antidepressive Agents, Depression, Major Depressive Disorder, Humans, Ketamine, Cognitive Behavioral Therapy, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.